奥赛康连跌4天，中欧基金旗下1只基金位列前十大股东

Group 1 - Aoscicon has experienced a decline for four consecutive trading days, with a cumulative drop of -5.20% [1] - Beijing Aoscicon Pharmaceutical Co., Ltd. was established in 2003 and originated from one of the earliest private new drug research institutions in Jiangsu Province, Nanjing Haiguang Applied Chemistry Research Institute [1] Group 2 - The financial report indicates that the China Europe Fund's China Europe Medical Health Mixed A has entered the top ten shareholders of Aoscicon, marking a new entry in the second quarter of this year [2] - The fund has achieved a year-to-date return of 25.26%, ranking 1433 out of a total of 4493 in its category [2] Group 3 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan holding a Ph.D. in Biomedical Engineering from Northwestern University in the United States [5][6] - Ge Lan has been with China Europe Fund since October 2014 and has managed several funds, currently serving as the manager of China Europe Medical Health Mixed Fund since September 29, 2016 [5][6] Group 4 - Zhao Lei, another fund manager, has a master's degree and has previously worked as a researcher and co-chief analyst in the pharmaceutical and biotechnology sector [7] - Zhao Lei joined China Europe Fund in May 2021 and is currently the manager of China Europe Medical Health Mixed A and C funds, with a recent performance of 12.97% and 13.09% respectively since July 4, 2025 [7] Group 5 - China Europe Fund Management Co., Ltd. was established in July 2006, with a current structure of 25 shareholders, including significant stakes held by WP Asia Pacific Asset Management LLC and Guodu Securities Co., Ltd. [7]